Cargando…

Skin Toxicity as a Predictor of Survival in Metastatic Colorectal Cancer Patients Treated with Anti-EGFR: Fact or Fallacy?

SIMPLE SUMMARY: Targeted therapy and chemotherapy are the mainstays of treatment to improve the survival of patients with metastatic colorectal cancer (mCRC). When RAS and BRAF genes are normal, a molecular target treatment with an anti-EGFR antagonist is prescribed. Anti-EGFR antagonists induce ski...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiang, Ting-Yu, Hsu, Hung-Chih, Chern, Yih-Jong, Liao, Chun-Kai, Hsu, Yu-Jen, Tsai, Wen-Sy, Hsieh, Pao-Shiu, Lin, Yu-Fen, Lee, Hsiu-Lan, You, Jeng-Fu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046585/
https://www.ncbi.nlm.nih.gov/pubmed/36980549
http://dx.doi.org/10.3390/cancers15061663
_version_ 1785013710176124928
author Chiang, Ting-Yu
Hsu, Hung-Chih
Chern, Yih-Jong
Liao, Chun-Kai
Hsu, Yu-Jen
Tsai, Wen-Sy
Hsieh, Pao-Shiu
Lin, Yu-Fen
Lee, Hsiu-Lan
You, Jeng-Fu
author_facet Chiang, Ting-Yu
Hsu, Hung-Chih
Chern, Yih-Jong
Liao, Chun-Kai
Hsu, Yu-Jen
Tsai, Wen-Sy
Hsieh, Pao-Shiu
Lin, Yu-Fen
Lee, Hsiu-Lan
You, Jeng-Fu
author_sort Chiang, Ting-Yu
collection PubMed
description SIMPLE SUMMARY: Targeted therapy and chemotherapy are the mainstays of treatment to improve the survival of patients with metastatic colorectal cancer (mCRC). When RAS and BRAF genes are normal, a molecular target treatment with an anti-EGFR antagonist is prescribed. Anti-EGFR antagonists induce skin responses in 50–70% of patients. There is an ongoing debate about whether the severe skin reactions brought on by anti-EGFR antagonists are associated with overall survival (OS) and progression-free survival (PFS). mCRC patients who received anti-EGFR therapy between October 2017 and October 2018 were retrospectively evaluated. Treatment with an anti-EGFR medication in the first-line setting was significantly associated with OS and PFS. In grades 1 and 2, there was no difference in the incidence of acne between males and females, although in grades 3 and 4, males were at a higher risk than females. In this study, skin toxicity did not predict the effectiveness of the anti-EGFR medication. ABSTRACT: The primary treatment for metastatic colorectal cancer (mCRC) consists of targeted therapy and chemotherapy to improve survival. A molecular target drug with an anti-epidermal growth factor receptor (EGFR) antagonist is recommended when the RAS and BRAF genes are normal. About 50–70% of patients using anti-EGFR antagonists will experience skin reactions. Some studies have shown that severe skin reactions caused by anti-EGFR antagonists may be linked to overall survival (OS) and progression-free survival (PFS), but the results are still uncertain. These data of mCRC patients who underwent anti-EGFR therapy between October 2017 and October 2018 were analyzed retrospectively. A total of 111 patients were included in this study. The survival results showed that gender, age, body mass index, primary tumor site, and recurrence did not significantly affect OS and PFS. However, the first-line anti-EGFR inhibitor treatment was significantly associated with OS (p < 0.001) and PFS (p < 0.001). There was no significant difference in the incidence of acne between males and females in grades 1 and 2, while males have a greater risk in grades 3 and 4 than females (20.3 vs. 4.8%; p-value = 0.041). Skin toxicity was not a predictor of anti-EGFR treatment response in this investigation.
format Online
Article
Text
id pubmed-10046585
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100465852023-03-29 Skin Toxicity as a Predictor of Survival in Metastatic Colorectal Cancer Patients Treated with Anti-EGFR: Fact or Fallacy? Chiang, Ting-Yu Hsu, Hung-Chih Chern, Yih-Jong Liao, Chun-Kai Hsu, Yu-Jen Tsai, Wen-Sy Hsieh, Pao-Shiu Lin, Yu-Fen Lee, Hsiu-Lan You, Jeng-Fu Cancers (Basel) Article SIMPLE SUMMARY: Targeted therapy and chemotherapy are the mainstays of treatment to improve the survival of patients with metastatic colorectal cancer (mCRC). When RAS and BRAF genes are normal, a molecular target treatment with an anti-EGFR antagonist is prescribed. Anti-EGFR antagonists induce skin responses in 50–70% of patients. There is an ongoing debate about whether the severe skin reactions brought on by anti-EGFR antagonists are associated with overall survival (OS) and progression-free survival (PFS). mCRC patients who received anti-EGFR therapy between October 2017 and October 2018 were retrospectively evaluated. Treatment with an anti-EGFR medication in the first-line setting was significantly associated with OS and PFS. In grades 1 and 2, there was no difference in the incidence of acne between males and females, although in grades 3 and 4, males were at a higher risk than females. In this study, skin toxicity did not predict the effectiveness of the anti-EGFR medication. ABSTRACT: The primary treatment for metastatic colorectal cancer (mCRC) consists of targeted therapy and chemotherapy to improve survival. A molecular target drug with an anti-epidermal growth factor receptor (EGFR) antagonist is recommended when the RAS and BRAF genes are normal. About 50–70% of patients using anti-EGFR antagonists will experience skin reactions. Some studies have shown that severe skin reactions caused by anti-EGFR antagonists may be linked to overall survival (OS) and progression-free survival (PFS), but the results are still uncertain. These data of mCRC patients who underwent anti-EGFR therapy between October 2017 and October 2018 were analyzed retrospectively. A total of 111 patients were included in this study. The survival results showed that gender, age, body mass index, primary tumor site, and recurrence did not significantly affect OS and PFS. However, the first-line anti-EGFR inhibitor treatment was significantly associated with OS (p < 0.001) and PFS (p < 0.001). There was no significant difference in the incidence of acne between males and females in grades 1 and 2, while males have a greater risk in grades 3 and 4 than females (20.3 vs. 4.8%; p-value = 0.041). Skin toxicity was not a predictor of anti-EGFR treatment response in this investigation. MDPI 2023-03-08 /pmc/articles/PMC10046585/ /pubmed/36980549 http://dx.doi.org/10.3390/cancers15061663 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chiang, Ting-Yu
Hsu, Hung-Chih
Chern, Yih-Jong
Liao, Chun-Kai
Hsu, Yu-Jen
Tsai, Wen-Sy
Hsieh, Pao-Shiu
Lin, Yu-Fen
Lee, Hsiu-Lan
You, Jeng-Fu
Skin Toxicity as a Predictor of Survival in Metastatic Colorectal Cancer Patients Treated with Anti-EGFR: Fact or Fallacy?
title Skin Toxicity as a Predictor of Survival in Metastatic Colorectal Cancer Patients Treated with Anti-EGFR: Fact or Fallacy?
title_full Skin Toxicity as a Predictor of Survival in Metastatic Colorectal Cancer Patients Treated with Anti-EGFR: Fact or Fallacy?
title_fullStr Skin Toxicity as a Predictor of Survival in Metastatic Colorectal Cancer Patients Treated with Anti-EGFR: Fact or Fallacy?
title_full_unstemmed Skin Toxicity as a Predictor of Survival in Metastatic Colorectal Cancer Patients Treated with Anti-EGFR: Fact or Fallacy?
title_short Skin Toxicity as a Predictor of Survival in Metastatic Colorectal Cancer Patients Treated with Anti-EGFR: Fact or Fallacy?
title_sort skin toxicity as a predictor of survival in metastatic colorectal cancer patients treated with anti-egfr: fact or fallacy?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046585/
https://www.ncbi.nlm.nih.gov/pubmed/36980549
http://dx.doi.org/10.3390/cancers15061663
work_keys_str_mv AT chiangtingyu skintoxicityasapredictorofsurvivalinmetastaticcolorectalcancerpatientstreatedwithantiegfrfactorfallacy
AT hsuhungchih skintoxicityasapredictorofsurvivalinmetastaticcolorectalcancerpatientstreatedwithantiegfrfactorfallacy
AT chernyihjong skintoxicityasapredictorofsurvivalinmetastaticcolorectalcancerpatientstreatedwithantiegfrfactorfallacy
AT liaochunkai skintoxicityasapredictorofsurvivalinmetastaticcolorectalcancerpatientstreatedwithantiegfrfactorfallacy
AT hsuyujen skintoxicityasapredictorofsurvivalinmetastaticcolorectalcancerpatientstreatedwithantiegfrfactorfallacy
AT tsaiwensy skintoxicityasapredictorofsurvivalinmetastaticcolorectalcancerpatientstreatedwithantiegfrfactorfallacy
AT hsiehpaoshiu skintoxicityasapredictorofsurvivalinmetastaticcolorectalcancerpatientstreatedwithantiegfrfactorfallacy
AT linyufen skintoxicityasapredictorofsurvivalinmetastaticcolorectalcancerpatientstreatedwithantiegfrfactorfallacy
AT leehsiulan skintoxicityasapredictorofsurvivalinmetastaticcolorectalcancerpatientstreatedwithantiegfrfactorfallacy
AT youjengfu skintoxicityasapredictorofsurvivalinmetastaticcolorectalcancerpatientstreatedwithantiegfrfactorfallacy